Filters
Findings from the phase III RESILIENT study show that a sublingual formulation of cyclobenzaprine (CBP SL) may benefit individuals with fibromyalgia.
Rheumatic and musculoskeletal diseases (RMD) may negatively impact sexual well-being, a study suggests.
New drug applications approved by US FDA as of 1-15 May 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
A significant proportion of rheumatology patients have been diagnosed with anxiety, depression, or fibromyalgia (FM), reveals a study, noting the importance of including screening for clinical decisions at all routine encounters.
Patients with radiographic axial spondyloarthritis (r-axSpA) who have been exposed to tumour necrosis factor inhibitor (TNFi) and interleukin (IL)-17 inhibitor (IL-17i) appear to have a lower risk of osteoporosis, but not hip fracture, than biologic disease-modifying antirheumatic drug (bDMARD)-naïve individuals, a recent study has shown.
Prioritizing physical activity (PA) intensity over volume may yield greater benefits for preventing most noncommunicable diseases (NCDs), a prospective study suggests.
Difficult-to-treat rheumatoid arthritis is associated with smoking, obesity, fibromyalgia, and depression, according to the results of a meta-analysis.
Treatment with leflunomide in combination with hydroxychloroquine has been proven to be beneficial, helping reduce disease activity in patients with systemically active Sjögren’s disease, in the phase 2b RepurpSS-II trial.
Antibiotics seem to do nothing in terms of reducing pain in patients with chronic low back pain and disc herniation, a study has shown.
Taking ixekizumab and tirzepatide together results in higher rates of skin clearance and weight loss compared with ixekizumab alone in patients with psoriasis and overweight or obesity, who represent a population that is difficult to treat, according to the phase IIIb TOGETHER-PsO trial.
